Targeting ischaemia
novel ischaemia targeting drugs for the treatment of Ventricular Arrhythmia (VA)
BioTherics has developed an exciting new drug to help people survive Sudden Cardiac Arrest.
Ischaemia is a restriction in blood supply to tissues, resulting in a shortage of oxygen and glucose needed for normal cellular metabolism (to keep tissue alive). Ischaemia is generally caused by problems with blood vessels, with resultant damage or dysfunction of cardiac tissue.
Opportunity
BioTherics has developed a novel ischaemia-activated prodrug for the treatment of Ventricular Arrhythmia. The technology is at an early stage, but results from preclinical trials are very exciting. The company is currently seeking investment to progress its development plans.